Clinical Relevance of Prognostic and Predictive Molecular Markers in Gliomas.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Advances and technical standards in neurosurgery

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-319-21359-0_4PMID 26508407
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Central Nervous System Cancers, Version 1.2015.

  2015cited by this paper
• EGFR and EGFRvIII analysis in glioblastoma as therapeutic biomarkers

  2015cited by this paper
• Changing incidence and improved survival of gliomas.

  2014cited by this paper
• Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.

  2014cited by this paper
• IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection.

  2014cited by this paper
• Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients

  2014cited by this paper
• Accuracy of 2-hydroxyglutarate quantification by short-echo proton-MRS at 3 T: a phantom study.

  2014cited by this paper
• BRAF-V600E mutation in pediatric and adult glioblastoma.

  2014cited by this paper
• MGMT promoter methylation in plasma of glioma patients receiving temozolomide

  2014cited by this paper
• ATRX Dysfunction Induces Replication Defects in Primary Mouse Cells

  2014cited by this paper
• Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma

  2014cited by this paper
• The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.

  2014cited by this paper
• Targeting BRAF in pediatric brain tumors.

  2014cited by this paper
• Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate.

  2013cited by this paper
• Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

  2013cited by this paper
• ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis

  2013cited by this paper
• Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

  2013cited by this paper
• An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells

  2013cited by this paper
• Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective.

  2013cited by this paper
• IDH mutations in tumorigenesis and their potential role as novel therapeutic targets.

  2013cited by this paper
• Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.

  2013cited by this paper
• The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas

  2013cited by this paper
• Phase III clinical trials that integrate treatment and biomarker evaluation.

  2013cited by this paper
• The role of MGMT testing in clinical practice: a report of the association for molecular pathology.

  2013cited by this paper
• Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

  2013cited by this paper
• Interlaboratory comparison of IDH mutation detection

  2013cited by this paper
• Molecular neuro-oncology in clinical practice: a new horizon.

  2013cited by this paper
• Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation

  2013cited by this paper
• Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status

  2013cited by this paper
• Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations

  2012cited by this paper
• Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma

  2012cited by this paper
• Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

  2012cited by this paper
• Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.

  2012cited by this paper
• Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

  2012cited by this paper
• Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma

  2012cited by this paper
• Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy

  2012cited by this paper
• Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.

  2012cited by this paper
• Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo.

  2012cited by this paper
• Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

  2012cited by this paper
• Molecular predictors of outcome in low-grade glioma.

  2012cited by this paper
• IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

  2012cited by this paper
• Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: A radiographic study in 358 de novo human glioblastomas

  2012cited by this paper
• IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

  2011cited by this paper
• Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

  2011cited by this paper
• Molecular diagnostics of gliomas.

  2011cited by this paper
• Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients.

  2011cited by this paper
• Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.

  2011cited by this paper
• Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas

  2011cited by this paper
• Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic?

  2011cited by this paper
• Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

  2010cited by this paper
• IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

  2010cited by this paper
• Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors

  2010cited by this paper
• Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods

  2010cited by this paper
• Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.

  2010cited by this paper
• Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis

  2010cited by this paper
• Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

  2010cited by this paper
• Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.

  2010cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2010cited by this paper
• Randomized clinical trials with biomarkers: design issues.

  2010cited by this paper
• Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades.

  2010cited by this paper
• Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

  2009cited by this paper
• Recurring mutations found by sequencing an acute myeloid leukemia genome.

  2009cited by this paper
• Use of archived specimens in evaluation of prognostic and predictive biomarkers.

  2009cited by this paper
• Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas

  2009cited by this paper
• IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.

  2009cited by this paper
• Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma

  2009cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2009cited by this paper
• IDH1 and IDH2 mutations in gliomas.

  2009cited by this paper
• NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.

  2009cited by this paper
• Predicting MGMT Methylation Status of Glioblastomas from MRI Texture

  2009cited by this paper
• An Integrated Genomic Analysis of Human Glioblastoma Multiforme

  2008cited by this paper
• MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.

  2008cited by this paper
• Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells

  2008cited by this paper
• DNA methylation landscapes: provocative insights from epigenomics

  2008cited by this paper
• Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas

  2007cited by this paper
• A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.

  2006cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas

  2005cited by this paper
• MGMT gene silencing and benefit from temozolomide in glioblastoma.

  2005cited by this paper
• Distinct methylation profiles of glioma subtypes

  2003cited by this paper
• Prognostic factors for survival in adult patients with cerebral low-grade glioma.

  2002cited by this paper
• Repair of O6-alkylguanine by alkyltransferases

  2000cited by this paper
• Repair of O(6)-alkylguanine by alkyltransferases.

  2000cited by this paper
• A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis.

  1996cited by this paper
• Mutagenesis and Laue structures of enzyme intermediates: isocitrate dehydrogenase.

  1995cited by this paper
• Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.

  1994cited by this paper

• Risk factors for postoperative malignant progression of lower-grade gliomas: a systematic review and meta-analysis.

  2025cites this paper
• Identification of Prognostic and Diagnostic Biomarkers for Glioma Utilizing Immune System Gene Profiling

  2025cites this paper
• Caregivers' Perspective and Burden of The End-of-Life Phase of Patients With Glioblastoma: A Multicenter Retrospective Study.

  2024cites this paper
• Prognosis prediction via histological evaluation of cellular heterogeneity in glioblastoma

  2024cites this paper
• LncRNA NDUFA6-DT: A Comprehensive Analysis of a Potential LncRNA Biomarker and Its Regulatory Mechanisms in Gliomas

  2024cites this paper
• Identification of Novel Molecular and Clinical Biomarkers of Survival in Glioblastoma Multiforme Patients: A Study Based on The Cancer Genome Atlas Data

  2024cites this paper
• Diffusion heterogeneity and vascular perfusion in tumor and peritumoral areas for prediction of overall survival in patients with high-grade glioma.

  2023cites this paper
• Integrated profiling identifies CACNG3 as a prognostic biomarker for patients with glioma

  2023cites this paper
• Construction and Verification of an RNA-Binding Protein-Associated Prognostic Model for Gliomas

  2023cites this paper
• Forecasting Molecular Features in IDH-Wildtype Gliomas: The State of the Art of Radiomics Applied to Neurosurgery

  2023cites this paper
• Recent insights into the microRNA-dependent modulation of gliomas from pathogenesis to diagnosis and treatment

  2022cites this paper
• MicroRNA-575 acts as a novel oncogene via targeting multiple signaling pathways in glioblastoma.

  2022cites this paper
• Gliomas molecular markers: importance in treatment, prognosis and applicability in brazilian health system.

  2022influential citation
• Siglec10—An immunosuppressor and negative predictor of survival prognosis in gliomas

  2022cites this paper
• Letter to the Editor. Prediction model of IDH wild-type glioblastoma.

  2022cites this paper
• Radiomic Analysis of Contrast-Enhanced MRI Predicts DNA Copy-Number Subtype and Outcome in Lower-Grade Gliomas.

  2021cites this paper
• T2/T2-FLAIR mismatch sign as a predictive biomarker for anaplastic astrocytoma genetic profile

  2021cites this paper
• Biomarkers of gliomas and their impact on diagnosis, prognosis, and treatment

  2021cites this paper
• Role of stress granules in modulating senescence and promoting cancer progression: Special emphasis on glioma

  2021cites this paper
• High expression of TXNDC11 indicated unfavorable prognosis of glioma

  2021cites this paper
• Siglec10 as an Immunosuppressive and Tumorgenesis Signature for Prediction of Survival Prognosis in Gliomas

  2020cites this paper
• Biomarcadores radiológicos en RM para una aproximación al diagnóstico molecular en gliomas IDH-mutados (grado II y III)

  2020cites this paper
• MRI Morphometry in Brain Tumors: Challenges and Opportunities in Expert, Radiomic, and Deep-Learning-Based Analyses

  2020cites this paper
• Radiogenomics correlation between MR imaging features and mRNA-based subtypes in lower-grade glioma

  2020cites this paper
• Brain Tumors

  2020cites this paper
• PABPC1 relevant bioinformatic profiling and prognostic value in gliomas.

  2019cites this paper
• The diagnostic efficacy of amide proton transfer imaging in grading gliomas and predicting tumor proliferation

  2019cites this paper
• MicroRNA-374a Governs Aggressive Cell Behaviors of Glioma by Targeting Prokineticin 2

  2019cites this paper
• Integrated Transcriptomic Analysis of Necrosis-related Gene in Diffuse Gliomas

  2019cites this paper
• Amide proton transfer imaging might predict survival and IDH mutation status in high-grade glioma

  2019cites this paper
• Current and Future Trends on Diagnosis and Prognosis of Glioblastoma: From Molecular Biology to Proteomics

  2019cites this paper
• Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign

  2019cites this paper
• Glioblastoma Multiforme and Genetic Mutations: The Issue Is Not Over Yet. An Overview of the Current Literature

  2019cites this paper
• Rationale for Aggressive Resection and General Surgical Principles for Intracranial Gliomas.

  2018cites this paper
• Angela C Eckstrand

  2018cites this paper
• Oncogenic transgelin-2 is differentially regulated in isocitrate dehydrogenase wild-type vs. mutant gliomas

  2018cites this paper
• New Histopathological Diagnostic Terms and their Codes of the Central Nervous System (CNS) in the International Classification of Diseases for Oncology (ICD-O 3.1) and about the Turkish Version of ICD-O

  2018cites this paper
• Comparative analysis of the diffusion kurtosis imaging and diffusion tensor imaging in grading gliomas, predicting tumour cell proliferation and IDH-1 gene mutation status

  2018cites this paper
• Epidemiology and Overview of Gliomas.

  2018cites this paper
• MGMT promoter methylation and 1p/19q co-deletion of surgically resected pulmonary carcinoid and large-cell neuroendocrine carcinoma

  2018cites this paper
• Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications.

  2018cites this paper
• [The spectrum of genetic alterations in anaplastic gliomas: and anaplastic oligodendrogliomas].

  2017cites this paper
• Clinical Significance of Genes in the NeoTYPE Brain Tumor Profile

  2017cites this paper
• Molecular biology of glioblastoma: Classification and mutational locations.

  2017cites this paper
• T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project

  2017cites this paper
• Single vs. combination immunotherapeutic strategies for glioma

  2017cites this paper
• Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma

  2017cites this paper
• Glioma CpG Island Methylator Phenotype (G-CIMP): Biological and Clinical Implications

  2017cites this paper
• The impact of the 2016 world health organization classification of tumours of the central nervous system upon diagnosis and prognosis

  2017cites this paper
• Recent advances and future of immunotherapy for glioblastoma

  2016cites this paper
• The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients’ survival: a meta-analysis

  2016cites this paper